Abivax SA
Developing an oral miR-124 pathway modulator for ulcerative colitis and other inflammatory diseases.
Immunology / IBD · Oral small molecule / miR-124 modulation · Phase 3 complete / NDA planned Q4 2026
Developing an oral miR-124 pathway modulator for ulcerative colitis and other inflammatory diseases.
Immunology / IBD · Oral small molecule / miR-124 modulation · Phase 3 complete / NDA planned Q4 2026